DiscoverThe Genetics PodcastEP 36 Genomics England CEO Chris Wigley & Clinical Lead Richard Scott: sequencing 35,000 people with COVID19, the future of genomic medicine, and why patients are their 'north star'
EP 36 Genomics England CEO Chris Wigley & Clinical Lead Richard Scott: sequencing 35,000 people with COVID19, the future of genomic medicine, and why patients are their 'north star'

EP 36 Genomics England CEO Chris Wigley & Clinical Lead Richard Scott: sequencing 35,000 people with COVID19, the future of genomic medicine, and why patients are their 'north star'

Update: 2020-05-27
Share

Description

Why do some people have a severe response to COVID-19, and others seem to have no symptoms at all? Is the answer in our genes?



This week we talk to Chris Wigley, the CEO of Genomics England and Interim SRO for Data-NHSX, and Dr Richard Scott, the clinical lead for rare disease at Genomics England and consultant clinical geneticist at Great Ormond Street.



Genomics England has led the UK into a new world of medicine with genetic sequencing, and it’s only just starting. Today, we’re focusing on the recently announced large scale human genome sequencing project launched by Genomics England in regards to COVID-19. From understanding individual response and drug development, listen to what Genomics England are hoping to understand about COVID-19.



If you would like to volunteer for Genomics England's study on COVID19, sign up here: https://www.genomicsengland.co.uk/covid-19/

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

EP 36 Genomics England CEO Chris Wigley & Clinical Lead Richard Scott: sequencing 35,000 people with COVID19, the future of genomic medicine, and why patients are their 'north star'

EP 36 Genomics England CEO Chris Wigley & Clinical Lead Richard Scott: sequencing 35,000 people with COVID19, the future of genomic medicine, and why patients are their 'north star'

Sano Genetics